MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date

Thursday, June 23, 2016

12:00pm-1:30pm
Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea

A. Robichaux-Viehoever, A. Ananth, Y.M. Kim, A. Hanson-Kahn, R. Cox, G. Enns, J. Strober, M. Willing, B. Schlaggar, J. Bernstein, Y. Wu (San Francisco, CA, USA)

Pediatric movement disorder  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Clinical effects of pallidal stimulation in dystonia are quantitatively related to intracortical inhibition

A. Fecíková, V. Cejka, V. Capek, F. Ruzicka, V. Bocek, D. Štastná, I. Štetkárová, D. Urgošík, R. Jech (Praha, Czech Republic)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Clinical outcomes of pallidal and subthalamic nucleus deep brain stimulation in isolated cranial and cranio-cervical dystonia

N.S. Luthra, K.A. Dodenhoff, M. San Luciano, M.M. Volz, S.L. Heath, P.A. Starr, J.L. Ostrem (San Francisco, CA, USA)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Clinical profile of patients with writer’s cramp

H.S. Kaleagasi, O. Dogu (Mersin, Turkey)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard (Manchester, United Kingdom)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease

C. Ruffmann, I. Poggiolini, N. Bengoa-Vergniory, F. Baig, M. Rolinski, J. Klein, M.T. Hu, R. Wade-Martins, J. Alegre-Abarrategui, L. Parkkinen (Oxford, United Kingdom)

Other  ·  Exhibit Hall located in Hall B, Level 2
12:00pm-1:30pm
Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms

A. Turakhanov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2
  • «Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 53
  • Next Page»

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley